Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 8/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.58 |
| ▸ | HTT | P42858 | 5/20 | 0.58 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6849673 | 0.90 | TDP1 (0.66) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL24863183 | 0.83 | TDP1 (0.66) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL6442808 | 0.83 | TDP1 (1.00) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL8327961 | 0.82 | TDP1 (0.63) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| Hydrochloric Acid SCHEMBL6948782 | 0.81 | TDP1 (0.61) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL230330 | 0.80 | TDP1 (0.78) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL8146665 | 0.80 | MTNR1A (0.64) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL30294105 | 0.80 | TDP1 (0.84) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL3161153 | 0.80 | TDP1 (0.84) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL9814242 | 0.80 | TDP1 (0.84) | TDP1LMNASMN1; SMN2HTTEGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200199127-A1 | (HETERO)ARYLALKYLAMINO-PYRAZOLOPYRIDAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-06-25 | — | — | US | disclosed |
| EP-3630768-A1 | (HETERO)ARYLALKYLAMINO-PYRAZOLOPYRIDAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018219927-A1 | (HETERO)ARYLALKYLAMINO-PYRAZOLOPYRIDAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-12-06 | — | — | WO | disclosed |
| US-7989458-B2 | Pyrimidine derivatives as alk-5 inhibitors | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| WO-2008006583-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| US-6756384-B2 | TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. | NOVO NORDISK A/S (DK) | 2004-06-29 | — | — | US | disclosed |
| US-20030135056-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2003-07-17 | — | — | US | disclosed |
| EP-1268484-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-6437147-B1 | FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM | NOVO NORDISK (DK) | 2002-08-20 | — | — | US | disclosed |
| US-20020058659-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2002-05-16 | — | — | US | disclosed |
| WO-2001068652-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
| US-4737495-A | ANTIALLERGENS, ANTISCHEMIC, HYPOTENSIVE AGENTS | DR. KARL TOMAE, GMBH (DE) | 1988-04-12 | — | — | US | disclosed |
| EP-0204349-A2 | Heteroaromatic amine derivatives, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199127-A1 | (HETERO)ARYLALKYLAMINO-PYRAZOLOPYRIDAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ADRB2, ADRA2C, OPRD1 | TDP1 2157/4885LMNA 2782/4885SMN1; SMN2 2311/4885 |
| US-20030135056-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | TDP1 3695/4885LMNA 4098/4885SMN1; SMN2 3954/4885 |
| US-20020058659-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | TDP1 3695/4885LMNA 4098/4885SMN1; SMN2 3954/4885 |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | ALK, ACVR1, MUSK | TDP1 752/4885LMNA 1528/4885SMN1; SMN2 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.